# Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

> **NCT05519111** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 60 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Dronabinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05519111
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519111, "Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05519111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*